Search Within

Karima Yataghene

Formats
  1. Journal Article (9)
  2. Meeting Abstract (2)
Groups
  1. Neuro-Oncology Service (10)
  2. Pediatrics, Department of (10)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (9)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (9)
  5. GSK Faculty (9)
  6. Neuroblastoma Service (9)

More Groups

People
  1. Brian Kushner (9)
  2. Kim Kramer (9)
  3. Nai-Kong Cheung (9)
  4. Shakeel Modak (9)
  5. Michael La Quaglia (4)
  6. Ellen Basu (3)

More People

Years
  1. 2020 (1)
  2. 2017 (1)
  3. 2016 (1)
  4. 2015 (1)
  5. 2014 (1)
  6. 2012 (1)

More Years

Publications
  1. Journal of Clinical Oncology (3)
  2. Oncotarget (2)
  3. Cancer (1)
  4. European Journal of Cancer (1)
  5. International Journal of Radiation Oncology, Biology, Physics (1)
  6. Neuro-Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (3)
  2. Elsevier Inc. (2)
  3. Impact Journals (2)
  4. Landes Bioscience (1)
  5. Oxford University Press (1)
  6. Wiley Blackwell (1)

More Publishers

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MSK eConsent: Digitalizing the informed consent process to improve participant engagement and understanding
    Meeting Abstract

    Buckley, M. T.; Lengfellner, J. M.; Koch, M. J.; Search, B.; Hoidra, C.; Lin, M.; Kundu, S.; Cambria, R.; O'Shea, M.; Galle, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • MYCN-amplified stage 2/3 neuroblastoma: Excellent survival in the era of anti-G(D2) immunotherapy
    Journal Article

    Kushner, B. H.; LaQuaglia, M. P.; Modak, S.; Wolden, S. L.; Basu, E. M.; Roberts, S. S.; Kramer, K.; Yataghene, K.; Cheung, I. Y.; Cheung, N. V.
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin
    Journal Article

    Kushner, B. H.; Ostrovnaya, I.; Cheung, I. Y.; Kuk, D.; Modak, S.; Kramer, K.; Roberts, S. S.; Basu, E. M.; Yataghene, K.; Cheung, N. K. V.
    Oncotarget (2016)

    Fulltext@MSK | Save
  • Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: A prospective phase II study
    Journal Article

    Kushner, B. H.; Ostrovnaya, I.; Cheung, I. Y.; Kuk, D.; Kramer, K.; Modak, S.; Yataghene, K.; Cheung, N. K. V.
    OncoImmunology (2015)

    Fulltext@MSK | Save
  • Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era
    Journal Article

    Kushner, B. H.; Modak, S.; Kramer, K.; LaQuaglia, M. P.; Yataghene, K.; Basu, E. M.; Roberts, S. S.; Cheung, N. K. V.
    Cancer (2014)

    Fulltext@MSK | Save
  • Weekly carboplatin-onlyoffers similar survival to vincristine/carboplatin in low-grade gliomas
    Meeting Abstract

    Gilheeney, S.; Jamzadeh, A.; Winchester, M.; Yataghene, K.; De Braganca, K.; Khakoo, Y.; Lyden, D.; Dunkel, I.
    Neuro-Oncology (2012)

    Fulltext@MSK | Save
  • High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma
    Journal Article

    Kushner, B. H.; Kramer, K.; Modak, S.; Yataghene, K.; Cheung, N. K. V.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
    Journal Article

    Kushner, B. H.; Kramer, K.; Modak, S.; Qin, L. X.; Yataghene, K.; Jhanwar, S. C.; Cheung, N. K. V.
    Pediatric Blood and Cancer (2009)

    Fulltext@MSK | Save
  • Hyperfractionated Low-Dose (21 Gy) Radiotherapy for Cranial Skeletal Metastases in Patients With High-Risk Neuroblastoma
    Journal Article

    Kushner, B. H.; Cheung, N. K. V.; Barker, C. A.; Kramer, K.; Modak, S.; Yataghene, K.; Wolden, S. L.
    International Journal of Radiation Oncology, Biology, Physics (2009)

    Fulltext@MSK | Save
  • Event-free survival of patients with high-risk neuroblastoma treated with an N6-like induction treatment - Reply
    Journal Article

    Kushner, B. H.; Kramer, K.; LaQuaglia, M. P.; Modak, S.; Yataghene, K.; Cheung, N. K. V.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save